I. Dittrich

[The cell morphology of peritoneal exudate in the course of bacterial peritonitis (experimental animal studies)].

1988Zeitschrift fur experimentelle Chirurgie, Transplantation, und kunstliche Organe : Organ der Sektion Experimentelle Chirurgie der Gesellschaft fur Chirurgie der DDR1 citations

Semantic Scholar

I. Dittrich

Most-cited papers

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.

Somatostatin receptor scintigraphy in small-cell lung cancer: results of a multicenter study.

Multicenter randomized trial for stage IIIB/IV non-small-cell lung cancer using every-3-week versus weekly paclitaxel/carboplatin.

[Recommendations for quality standards in bronchoscopy].

Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO

NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.

Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.

Effect of performance status (ECOG PS) on treatment outcome with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after first-line (1L) immune checkpoint inhibitor (ICI) combination therapy.

9146 Long term benefit from erlotinib treatment is independent of prognostic factors and therapeutic response

Clinical phase II trial of intravenous treosulfan in patients with non-pretreated metastatic small-cell lung cancer

Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial.

1143P Effect of best response to first-line (1L) treatment (tx) on outcomes with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after 1L immune checkpoint inhibitor (ICI) combination therapy

The therapy of the inoperable non small cell lung cancer: Radiotherapy vs. radio-chemotherapy

[The cell morphology of peritoneal exudate in the course of bacterial peritonitis (experimental animal studies)].

1330P Second-line nintedanib + docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: Updated efficacy and safety results from VARGADO Cohort C

Are dose volume histograms a valuable tool in predicting clinically significant pneumonitis using conformal radiotherapy in locally advanced NSCLC

Therapy of the small cell lung cancer — Comparison two established chemotherapy regime (ACO vs. CEV)

Non tumor conditional death of patients with small cell lung cancer

Small cell lung cancer: Stage, therapy, surviving — Analysis of a non selected patient collective 1993–1997

Mitomycin/vindesine in the treatment of advanced non-small-cell lung cancer -phase IV study